Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Current Liabilities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Total Current Liabilities for 7 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 18.15% to $13.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, up 18.15% year-over-year, with the annual reading at $13.0 million for FY2025, 18.15% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $13.0 million at Fulcrum Therapeutics, up from $11.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $22.6 million in Q1 2021, with the low at $8.1 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $15.2 million, with a median of $14.5 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 61.44% in 2021, then tumbled 33.08% in 2023.
  • Over 5 years, Total Current Liabilities stood at $19.2 million in 2021, then fell by 12.89% to $16.7 million in 2022, then fell by 18.24% to $13.7 million in 2023, then decreased by 19.24% to $11.0 million in 2024, then grew by 18.15% to $13.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $13.0 million, $11.6 million, and $9.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.